Roche ($RHHBY) may have to circle the wagons around its targeted melanoma drug Zelboraf. Positive data on two GlaxoSmithKline ($GSK) melanoma treatments have analysts predicting a quick assault on market share once they're approved, possibly next year. And Glaxo plans a head-to-head study combining the two experimental drugs against--you guessed it--Zelboraf. Report